Incretin-based therapies for cardio-kidney-liver-metabolic disease: the role of the liver in the modern era of chronic disease management
Steatotic liver disease (SLD) is a leading cause of disease globally and demands new therapeutic approaches to mitigate underlying metabolic dysregulation. Incretin-based therapies are emerging as a viable prospect to fulfil this unmet niche. A literature review to inform the evidence base for incretin focussed pharmacology in the metabolic liver diseases space and an informed commentary on unmet areas of need. Incretin-based therapeutics demonstrate multifarious benefits across the chronic metabolic disease spectrum with promising data across the continuum of pathology.
Authors
- Jacob George (ORCID: https://orcid.org/0000-0002-8421-5476)
- Ming‐Hua Zheng (ORCID: https://orcid.org/0000-0003-4984-2631)
- Mazen Noureddin (ORCID: https://orcid.org/0000-0003-2127-2040)
- Rohit Seth Loomba (ORCID: https://orcid.org/0000-0002-4845-9991)
- Mark Dhinesh Muthiah (ORCID: https://orcid.org/0000-0002-9724-4743)
- Harendran Elangovan
- Jörn M. Schattenberg (ORCID: https://orcid.org/0000-0002-4224-4703)
- Christos S. Mantzoros
Institutions
- University of San Diego (US)
- Wenzhou Medical University (CN)
- Beth Israel Deaconess Hospital (US)
- First Affiliated Hospital of Wenzhou Medical University (CN)
- Westmead Hospital (AU)
- University of California San Diego (US)
- Methodist Hospital (US)
- Westmead Institute (AU)
- Westmead Institute for Medical Research (AU)
- National University Hospital (SG)
- Saarland University (DE)
Publication Details
- Journal
- Clinical and Molecular Hepatology
- Published
- 2025-10-28
- DOI
- https://doi.org/10.3350/cmh.2025.0857
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Cancer Research Institute
- Medical Research Council
- National Health and Medical Research Council